Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets 12:25:32 2026-06-01 EDT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	+9,900.00%

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 87.26K 82.62K 74.89K 140K 9.68M 141K 981K 377K 4.92M 380K 372K 15.55M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.76M 9.25M 8.38M 15.72M 1.08B 15.8M 110M 42.23M 551M 42.56M 41.63M 1.74B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
25-10-14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-08-15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
25-04-30	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
25-04-29	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
24-11-15	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
24-10-17	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
24-10-15	Top Midday Decliners	MT
24-10-14	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
24-09-27	Top Midday Decliners	MT
24-09-24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24-09-24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

23-09-21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
23-09-21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
23-09-21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
23-03-24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation : Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations : Seelos Therapeutics, Inc.

Press Releases : Seelos Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Annual profits - Rate of surprise

24-11-22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24-10-24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-10-24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
24-10-15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
24-10-15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		3,878.4
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	2018-12-31
Michael Golembiewski DFI	Director of Finance/CFO	54	2021-08-31
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/29/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
1/12/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
1/12/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	+9,900.00%	-100.00%	136
WUXI APPTEC CO., LTD.	-2.11%	-1.68%	+44.52%	+95.15%	66.93B
ARGENX SE	-0.23%	-4.45%	+30.39%	+73.64%	61.97B
INSMED INCORPORATED	+1.67%	+2.47%	-11.23%	+388.34%	28.27B
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-4.43%	+30.56%	+10.07%	24.59B
BIONTECH SE	+0.34%	-6.78%	-7.27%	-17.99%	24.3B
GENMAB A/S	+0.43%	-3.37%	+14.85%	-19.29%	19.41B
PHARMAESSENTIA CORPORATION	-3.03%	-2.29%	+185.12%	+334.07%	16.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-4.94%	-5.29%	+495.65%	14.18B
EXELIXIS, INC.	-2.28%	-4.90%	+43.64%	+155.21%	13.91B
Average	+989.18%	-3.11%	+1,022.53%	+141.48%	27.03B
Weighted average by Cap.	-0.84%	-3.06%	+33.46%	+133.67%

	2022	2023
Net sales	-	2.2 1.9 1.8 1.63 3.06 210.46 3.07 21.35 8.21 107.08 8.27 8.09 338.35
Net income	-73.53M -63.36M -59.99M -54.38M -102M -7.03B -103M -713M -274M -3.57B -276M -270M -11.29B	-37.88M -32.64M -30.9M -28.01M -52.55M -3.62B -52.82M -367M -141M -1.84B -142M -139M -5.82B
Net Debt	4.59M 3.95M 3.74M 3.39M 6.37M 438M 6.4M 44.46M 17.1M 223M 17.23M 16.86M 705M	11.23M 9.68M 9.16M 8.31M 15.58M 1.07B 15.66M 109M 41.85M 546M 42.18M 41.26M 1.73B